<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-10-01" updated="2020-01-02">
  <drugbank-id primary="true">DB09146</drugbank-id>
  <drugbank-id>DB06790</drugbank-id>
  <name>Iron sucrose</name>
  <description>Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients.</description>
  <cas-number>8047-67-4</cas-number>
  <unii>FZ7NYF5N8L</unii>
  <average-mass>866.546</average-mass>
  <monoisotopic-mass>866.764181</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links>
      <link>
        <ref-id>L222</ref-id>
        <title>monograph</title>
        <url>https://www.drugs.com/monograph/iron-sucrose.html</url>
      </link>
      <link>
        <ref-id>L238</ref-id>
        <title>article</title>
        <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805051/</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Iron sucrose is elemental iron as an injection. It replenishes body iron stores in patients with iron deficiency.</indication>
  <pharmacodynamics>Significant increases in serum iron and serum ferritin and significant decreases in total iron binding capacity occurred four weeks from the initiation of iron sucrose treatment.</pharmacodynamics>
  <mechanism-of-action>Following intravenous administration, iron sucrose is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron  is then incorporated into hemoglobin as the cells mature into red blood cells.</mechanism-of-action>
  <toxicity>Hypersensitivity reactions, including anaphylactic shock, loss of consciousness, collapse, hypotension, dyspnea, and seizure.&#13;
Monitor iron toxicity through the periodic evaluation of lab works which monitor the body concentration of iron. Lab monitoring of the following parameters: transferrin saturation, serum ferritin concentrations, hemoglobin, and hematocrit could be helpful to avoid iron overload.&#13;
Severe allergic symptoms include: rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); burning or pain at the injection site; burning, numbness, or tingling; chest pain; fainting; loss of consciousness; severe or persistent dizziness, headache, or light-headedness; seizures; shortness of breath; swelling of the hands, ankles, or feet. </toxicity>
  <metabolism>Following IV administration, dissociated into iron and sucrose by the reticuloendothelial system.</metabolism>
  <absorption>The intravensously administered iron sucrose injection would result rapidly in high serum iron levels. Maximum measured levels occured after 10 min of injection with an average of 30.00 mg/l.</absorption>
  <half-life>6 hours.</half-life>
  <protein-binding>It binds with transferrin.</protein-binding>
  <route-of-elimination>Renal elimination of iron contributed very little to the total elimination (in average less than 5%).&#13;
While, renal elimination of sucrose accounts for 68-75% of the administered dose after 4 and 24 hours respectively. </route-of-elimination>
  <volume-of-distribution>Vd is 7.3 L</volume-of-distribution>
  <clearance>Total body clearance is 20.5 ml/min.</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.</description>
    <direct-parent>O-glycosyl compounds</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic oxygen compounds</superclass>
    <class>Organooxygen compounds</class>
    <subclass>Carbohydrates and carbohydrate conjugates</subclass>
    <alternative-parent>C-glycosyl compounds</alternative-parent>
    <alternative-parent>Disaccharides</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Ketals</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic oxoanionic compounds</alternative-parent>
    <alternative-parent>Organic sodium salts</alternative-parent>
    <alternative-parent>Organic transition metal salts</alternative-parent>
    <alternative-parent>Organic zwitterions</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Oxanes</alternative-parent>
    <alternative-parent>Polyols</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Tetrahydrofurans</alternative-parent>
    <substituent>Acetal</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic heteromonocyclic compound</substituent>
    <substituent>C-glycosyl compound</substituent>
    <substituent>Disaccharide</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Ketal</substituent>
    <substituent>O-glycosyl compound</substituent>
    <substituent>Organic alkali metal salt</substituent>
    <substituent>Organic hydroxide</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organic sodium salt</substituent>
    <substituent>Organic transition metal salt</substituent>
    <substituent>Organic zwitterion</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Oxane</substituent>
    <substituent>Polyol</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Tetrahydrofuran</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Ferric hydroxide sucrose complex</synonym>
    <synonym language="english" coder="">Iron oxide saccharated</synonym>
    <synonym language="english" coder="">Iron saccharate</synonym>
    <synonym language="english" coder="ban/usan/usp">Iron sucrose</synonym>
    <synonym language="english" coder="">Iron sucrose complex</synonym>
    <synonym language="english" coder="">Iron sugar</synonym>
    <synonym language="english" coder="">Iron(III) hydroxide sucrose complex</synonym>
    <synonym language="english" coder="">Saccharated ferric oxide</synonym>
    <synonym language="english" coder="">Saccharated iron</synonym>
    <synonym language="english" coder="">Saccharated iron oxide</synonym>
    <synonym language="english" coder="">Sucroferric oxyhydroxide</synonym>
  </synonyms>
  <products>
    <product>
      <name>Bal-Care DHA</name>
      <labeller>Pru Gen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>42546-180</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bal-Care DHA Essential</name>
      <labeller>Pru Gen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>42546-185</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Choice OB DHA</name>
      <labeller>Acella Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>42192-353</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-17</started-marketing-on>
      <ended-marketing-on>2015-07-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HemeNatal OB</name>
      <labeller>Wh Nutritionals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>76331-901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HemeNatal OB plus DHA</name>
      <labeller>Wh Nutritionals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>76331-904</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-08</started-marketing-on>
      <ended-marketing-on>2019-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hemetab</name>
      <labeller>Wh Nutritionals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>76331-900</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-01</started-marketing-on>
      <ended-marketing-on>2020-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Marnatal F</name>
      <labeller>Marnel Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0682-1570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myferon 150</name>
      <labeller>Martin Ekwealor Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58607-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myferon 150 Forte</name>
      <labeller>Martin Ekwealor Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58607-112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PNV-First</name>
      <labeller>Acella Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>42192-350</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-17</started-marketing-on>
      <ended-marketing-on>2015-06-30</ended-marketing-on>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Poly-Vi-Flor with Iron</name>
      <labeller>Cerecor, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>23594-600</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PreferaOB</name>
      <labeller>Meda Pharmaceuticals Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>0037-0084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2018-09-21</ended-marketing-on>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PreferaOB ONE</name>
      <labeller>Meda Pharmaceuticals Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>0037-0086</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2018-09-21</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PreferaOB plus DHA</name>
      <labeller>Meda Pharmaceuticals Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>0037-0083</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-01</started-marketing-on>
      <ended-marketing-on>2018-09-21</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Velphoro</name>
      <labeller>Vifor Fresenius Medical Care Renal Pharma Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02471574</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>500 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Venofer</name>
      <labeller>Fresenius Medical Care North America</labeller>
      <ndc-id/>
      <ndc-product-code>49230-103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-04</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021135</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Venofer</name>
      <labeller>Fresenius Medical Care North America</labeller>
      <ndc-id/>
      <ndc-product-code>49230-532</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-11-06</started-marketing-on>
      <ended-marketing-on>2010-12-22</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>75 mg/3.75mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021135</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Venofer</name>
      <labeller>Fresenius Medical Care Holdings, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49230-530</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021135</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Venofer</name>
      <labeller>Fresenius Medical Care Holdings, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49230-534</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021135</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Venofer</name>
      <labeller>AMERICAN REGENT, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0517-2325</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021135</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Venofer</name>
      <labeller>AMERICAN REGENT, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0517-2310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021135</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Venofer</name>
      <labeller>AMERICAN REGENT, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0517-2340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021135</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vp-heme Ob</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>76439-237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-14</started-marketing-on>
      <ended-marketing-on>2016-05-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vp-heme Ob</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69543-237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vp-heme Ob DHA</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>76439-238</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-01</started-marketing-on>
      <ended-marketing-on>2016-02-05</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>VP-HEME One</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>76439-240</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-01</started-marketing-on>
      <ended-marketing-on>2016-05-31</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>VP-HEME One</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69543-240</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Colliron IV</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Encifer</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Fe-back</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Feojectin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Ferijet</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Ferosoft S</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Ferplex SS</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Ferrivenin</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>HemeNatal OB</name>
      <ingredients>alpha-Tocopherol succinate + Biotin + Cholecalciferol + Cupric sulfate + Cyanocobalamin + Folic acid + Heme iron polypeptide + Iron sucrose + Nicotinamide + Pantothenic acid + Potassium Iodide + Pyridoxine + Riboflavin + Selenic acid + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Bal-Care DHA Essential</name>
      <ingredients>Ascorbic acid + Beta carotene + Calcium carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + DL-alpha tocopheryl acetate + Folic acid + Iodine + Iron sucrose + Magnesium oxide + Nicotinamide + Omega-3 fatty acids + Pyridoxine + Riboflavin + Sodium feredetate + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Bal-Care DHA</name>
      <ingredients>Ascorbic acid + Beta carotene + Calcium carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + DL-alpha tocopheryl acetate + Folic acid + Iodine + Iron sucrose + Magnesium oxide + Nicotinamide + Omega-3 fatty acids + Pyridoxine + Riboflavin + Sodium feredetate + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Marnatal F</name>
      <ingredients>Ascorbic acid + Calcium carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + D-alpha-Tocopherol acetate + Folic acid + Iron sucrose + Magnesium oxide + Nicotinamide + Pyridoxine + Riboflavin + Thiamine</ingredients>
    </mixture>
    <mixture>
      <name>Myferon 150</name>
      <ingredients>Iron sucrose</ingredients>
    </mixture>
    <mixture>
      <name>Myferon 150 Forte</name>
      <ingredients>Cyanocobalamin + Folic acid + Iron sucrose</ingredients>
    </mixture>
    <mixture>
      <name>Choice OB DHA</name>
      <ingredients>Ascorbic acid + Beta carotene + Cholecalciferol + Cyanocobalamin + DL-alpha tocopheryl acetate + Doconexent + Folic acid + Iron sucrose + Magnesium oxide + Nicotinamide + Pyridoxine + Riboflavin + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>PreferaOB plus DHA</name>
      <ingredients>alpha-Tocopherol succinate + Biotin + Cholecalciferol + Cupric sulfate + Cyanocobalamin + Folic acid + Heme iron polypeptide + Iron sucrose + Nicotinamide + Pantothenic acid + Potassium Iodide + Pyridoxine + Riboflavin + Schizochytrium DHA oil + Selenic acid + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>PreferaOB</name>
      <ingredients>alpha-Tocopherol succinate + Biotin + Cholecalciferol + Cupric sulfate + Cyanocobalamin + Folic acid + Heme iron polypeptide + Iron sucrose + Nicotinamide + Pantothenic acid + Potassium Iodide + Pyridoxine + Riboflavin + Selenic acid + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>PreferaOB ONE</name>
      <ingredients>Ascorbic acid + Biotin + Cholecalciferol + Cyanocobalamin + DL-alpha tocopheryl acetate + Folic acid + Heme iron polypeptide + Iron sucrose + Nicotinamide + Pantothenic acid + Potassium Iodide + Pyridoxine + Schizochytrium DHA oil + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>VP-HEME One</name>
      <ingredients>alpha-Tocopherol acetate + Ascorbic acid + Biotin + Cholecalciferol + Cyanocobalamin + Doconexent + Folic acid + Heme iron polypeptide + Iron sucrose + Nicotinamide + Pantothenic acid + Potassium Iodide + Pyridoxine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Vp-heme Ob</name>
      <ingredients>alpha-Tocopherol succinate + Biotin + Cholecalciferol + Copper gluconate + Cyanocobalamin + Folic acid + Heme iron polypeptide + Iron sucrose + Nicotinamide + Pantothenic acid + Potassium Iodide + Pyridoxine + Riboflavin + Selenic acid + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Vp-heme Ob DHA</name>
      <ingredients>alpha-Tocopherol succinate + Biotin + Cholecalciferol + Cupric sulfate + Cyanocobalamin + Folic acid + Heme iron polypeptide + Iron sucrose + Niacin + Omega-3 fatty acids + Pantothenic acid + Potassium Iodide + Pyridoxine + Riboflavin + Selenic acid + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>PNV-First</name>
      <ingredients>Ascorbic acid + Beta carotene + Cholecalciferol + Cupric oxide + Cyanocobalamin + DL-alpha tocopheryl acetate + Folic acid + Iron sucrose + Magnesium oxide + Nicotinamide + Omega-3 fatty acids + Potassium Iodide + Pyridoxine + Riboflavin + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Venofer</name>
      <ingredients>Iron sucrose</ingredients>
    </mixture>
    <mixture>
      <name>Venofer</name>
      <ingredients>Iron sucrose</ingredients>
    </mixture>
    <mixture>
      <name>HemeNatal OB plus DHA</name>
      <ingredients>alpha-Linolenic acid + alpha-Tocopherol succinate + Biotin + Cholecalciferol + Cupric sulfate + Cyanocobalamin + Doconexent + Folic acid + Heme iron polypeptide + Iron sucrose + Nicotinamide + Osbond acid + Pantothenic acid + Potassium Iodide + Pyridoxine + Riboflavin + Selenic acid + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Hemetab</name>
      <ingredients>Cyanocobalamin + Folic acid + Heme iron polypeptide + Iron sucrose</ingredients>
    </mixture>
    <mixture>
      <name>Venofer</name>
      <ingredients>Iron sucrose</ingredients>
    </mixture>
    <mixture>
      <name>Venofer</name>
      <ingredients>Iron sucrose</ingredients>
    </mixture>
    <mixture>
      <name>Venofer</name>
      <ingredients>Iron sucrose</ingredients>
    </mixture>
    <mixture>
      <name>Venofer</name>
      <ingredients>Iron sucrose</ingredients>
    </mixture>
    <mixture>
      <name>Vp-heme Ob</name>
      <ingredients>alpha-Tocopherol succinate + Biotin + Cholecalciferol + Cupric sulfate + Cyanocobalamin + Folic acid + Heme iron polypeptide + Iron sucrose + Nicotinamide + Pantothenic acid + Potassium Iodide + Pyridoxine + Riboflavin + Selenic acid + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>VP-HEME One</name>
      <ingredients>alpha-Tocopherol acetate + Ascorbic acid + Biotin + Cholecalciferol + Cyanocobalamin + Doconexent + Folic acid + Heme iron polypeptide + Iron sucrose + Nicotinamide + Pantothenic acid + Potassium Iodide + Pyridoxine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Poly-Vi-Flor with Iron</name>
      <ingredients>alpha-Tocopherol acetate + Cholecalciferol + Fluoride ion + Iron sucrose + Levomefolic acid + Nicotinamide + Pyridoxine + Riboflavin + Thiamine</ingredients>
    </mixture>
    <mixture>
      <name>Venofer</name>
      <ingredients>Iron sucrose</ingredients>
    </mixture>
    <mixture>
      <name>Velphoro</name>
      <ingredients>Iron sucrose</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids, Acyclic</category>
      <mesh-id>D000144</mesh-id>
    </category>
    <category>
      <category>Antianemic Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Disaccharides</category>
      <mesh-id>D004187</mesh-id>
    </category>
    <category>
      <category>Drugs for Treatment of Hyperkalemia and Hyperphosphatemia</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ferric Compounds</category>
      <mesh-id>D005290</mesh-id>
    </category>
    <category>
      <category>Hematinics</category>
      <mesh-id>D006397</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hydroxy Acids</category>
      <mesh-id>D006880</mesh-id>
    </category>
    <category>
      <category>Iron Compounds</category>
      <mesh-id>D058085</mesh-id>
    </category>
    <category>
      <category>Iron Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Iron Trivalent, Oral Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Oligosaccharides</category>
      <mesh-id>D009844</mesh-id>
    </category>
    <category>
      <category>Organometallic Compounds</category>
      <mesh-id>D009942</mesh-id>
    </category>
    <category>
      <category>Parenteral Iron Replacement</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pharmaceutical Preparations</category>
      <mesh-id>D004364</mesh-id>
    </category>
    <category>
      <category>Phosphate Binder</category>
      <mesh-id/>
    </category>
    <category>
      <category>Phosphate-removing Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Polysaccharides</category>
      <mesh-id>D011134</mesh-id>
    </category>
    <category>
      <category>Sugar Acids</category>
      <mesh-id>D013400</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>150 mg/1</strength>
    </dosage>
    <dosage>
      <form>Suspension / drops</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule, liquid filled</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, chewable</form>
      <route>Oral</route>
      <strength>500 mg</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>75 mg/3.75mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>20 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B03AB02">
      <level code="B03AB">Iron trivalent, oral preparations</level>
      <level code="B03A">IRON PREPARATIONS</level>
      <level code="B03">ANTIANEMIC PREPARATIONS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
    <atc-code code="V03AE05">
      <level code="V03AE">Drugs for treatment of hyperkalemia and hyperphosphatemia</level>
      <level code="V03A">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V03">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>40:18.19</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents>
    <patent>
      <number>6174442</number>
      <country>United States</country>
      <approved>2001-01-16</approved>
      <expires>2016-12-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9561251</number>
      <country>United States</country>
      <approved>2017-02-07</approved>
      <expires>2030-01-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>Iron sucrose can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11404</drugbank-id>
      <name>Enrofloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>Iron sucrose can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The serum concentration of Doxycycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>The serum concentration of Lymecycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>The serum concentration of Clomocycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The serum concentration of Oxytetracycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>The serum concentration of Demeclocycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The serum concentration of Tetracycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>The serum concentration of Metacycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>The serum concentration of Sarecycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The serum concentration of Omadacycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13092</drugbank-id>
      <name>Meclocycline</name>
      <description>The serum concentration of Meclocycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>The serum concentration of Penimepicycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The serum concentration of Levothyroxine can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06782</drugbank-id>
      <name>Dimercaprol</name>
      <description>Dimercaprol may increase the nephrotoxic activities of Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00535</drugbank-id>
      <name>Cefdinir</name>
      <description>Iron sucrose can cause a decrease in the absorption of Cefdinir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08826</drugbank-id>
      <name>Deferiprone</name>
      <description>The serum concentration of Deferiprone can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>Iron sucrose can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>Iron sucrose can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>The bioavailability of Levodopa can be decreased when combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>Iron sucrose can cause a decrease in the absorption of Methyldopa resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>Iron sucrose can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00166</drugbank-id>
      <name>Lipoic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06824</drugbank-id>
      <name>Triethylenetetramine</name>
      <description>The serum concentration of Iron sucrose can be decreased when it is combined with Triethylenetetramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00085</drugbank-id>
      <name>Pancrelipase</name>
      <description>Pancrelipase can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>Aluminium can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>Magnesium oxide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01390</drugbank-id>
      <name>Sodium bicarbonate</name>
      <description>Sodium bicarbonate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>Aluminum hydroxide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>Calcium carbonate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>Magaldrate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>Magnesium hydroxide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>Magnesium trisilicate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>Magnesium carbonate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>Magnesium silicate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>Aluminium acetoacetate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>Hydrotalcite can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>Magnesium peroxide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>Almasilate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>Aluminium glycinate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13650</drugbank-id>
      <name>Aloglutamol</name>
      <description>Aloglutamol can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13829</drugbank-id>
      <name>Calcium silicate</name>
      <description>Calcium silicate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14517</drugbank-id>
      <name>Aluminium phosphate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>Pantoprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>Lansoprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>Esomeprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>Rabeprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05351</drugbank-id>
      <name>Dexlansoprazole</name>
      <description>Dexlansoprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13762</drugbank-id>
      <name>Dexrabeprazole</name>
      <description>Dexrabeprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15246</drugbank-id>
      <name>Salvianolic acid A</name>
      <description>Salvianolic acid A can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>Olanzapine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>Cimetidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>Nizatidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>Ranitidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>Famotidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>Methantheline can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Promethazine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Doxepin can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Asenapine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08805</drugbank-id>
      <name>Metiamide</name>
      <description>Metiamide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08806</drugbank-id>
      <name>Roxatidine acetate</name>
      <description>Roxatidine acetate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12770</drugbank-id>
      <name>Lafutidine</name>
      <description>Lafutidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12884</drugbank-id>
      <name>Lavoltidine</name>
      <description>Lavoltidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13760</drugbank-id>
      <name>Niperotidine</name>
      <description>Niperotidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00399</drugbank-id>
      <name>Zoledronic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00720</drugbank-id>
      <name>Clodronic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Clodronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Risedronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01077</drugbank-id>
      <name>Etidronic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Etidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Tiludronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06255</drugbank-id>
      <name>Incadronic acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Incadronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02369</drugbank-id>
      <name>3-Aza-2,3-Dihydrogeranyl Diphosphate</name>
      <description>Iron sucrose can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02423</drugbank-id>
      <name>Thiopyrophosphate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Thiopyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02552</drugbank-id>
      <name>Geranyl Diphosphate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Geranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04160</drugbank-id>
      <name>Pyrophosphoric acid</name>
      <description>Iron sucrose can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05143</drugbank-id>
      <name>OXI-4503</name>
      <description>Iron sucrose can cause a decrease in the absorption of OXI-4503 resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07841</drugbank-id>
      <name>Geranylgeranyl diphosphate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Geranylgeranyl diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09147</drugbank-id>
      <name>Ferric pyrophosphate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09413</drugbank-id>
      <name>Monopotassium phosphate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Monopotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09414</drugbank-id>
      <name>Dipotassium phosphate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09449</drugbank-id>
      <name>Sodium phosphate, monobasic</name>
      <description>Iron sucrose can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11348</drugbank-id>
      <name>Calcium Phosphate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11493</drugbank-id>
      <name>Sodium tripolyphosphate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Sodium tripolyphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13995</drugbank-id>
      <name>Ferric pyrophosphate citrate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14481</drugbank-id>
      <name>Calcium phosphate dihydrate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14523</drugbank-id>
      <name>Phosphate ion</name>
      <description>Iron sucrose can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09139</drugbank-id>
      <name>Technetium Tc-99m oxidronate</name>
      <description>Iron sucrose can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The absorption of Iron sucrose can be decreased when combined with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00190</drugbank-id>
      <name>Carbidopa</name>
      <description>Iron sucrose can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.99</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>9.52e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-4.5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>pentairon(3+) ion disodium (2R,3R,4S,5S,6R)-2-{[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol trihydrate hydroxide octaoxidandiide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>pentairon(3+) ion disodium sucrose trihydrate hydroxide octaoxidandiide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>866.546</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>866.764181</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H29Fe5Na2O23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C12H22O11.5Fe.2Na.4H2O.8O/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12;;;;;;;;;;;;;;;;;;;/h4-11,13-20H,1-3H2;;;;;;;;4*1H2;;;;;;;;/q;5*+3;2*+1;;;;;8*-2/p-1/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;/m1.................../s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>FWZTTZUKDVJDCM-CEJAUHOTSA-M</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>189.53</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>68.77</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>30.97</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>11</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>11.84</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>309</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>91663255</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>310265059</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>32699616</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Iron_sucrose</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1200823</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000130</id>
      <name>Hemoglobin subunit alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>component of</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L223</ref-id>
            <title>monograph</title>
            <url>http://www.rxlist.com/venofer-drug/clinical-pharmacology.htm</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P69905" source="Swiss-Prot">
        <name>Hemoglobin subunit alpha</name>
        <general-function>Oxygen transporter activity</general-function>
        <specific-function>Involved in oxygen transport from the lung to the various peripheral tissues.</specific-function>
        <gene-name>HBA1</gene-name>
        <locus>16p13.3</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.09</theoretical-pi>
        <molecular-weight>15257.405</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4823</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HBA1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J00153</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>386764</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P69905</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HBA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Alpha-globin</synonym>
          <synonym>Hemoglobin alpha chain</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036956|Hemoglobin subunit alpha
MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKGHG
KKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTP
AVHASLDKFLASVSTVLTSKYR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010173|Hemoglobin subunit alpha (HBA1)
ATGGTGCTGTCTCCTGCCGACAAGACCAACGTCAAGGCCGCCTGGGGTAAGGTCGGCGCG
CACGCTGGCGAGTATGGTGCGGAGGCCCTGGAGAGGATGTTCCTGTCCTTCCCCACCACC
AAGACCTACTTCCCGCACTTCGACCTGAGCCACGGCTCTGCCCAGGTTAAGGGCCACGGC
AAGAAGGTGGCCGACGCGCTGACCAACGCCGTGGCGCACGTGGACGACATGCCCAACGCG
CTGTCCGCCCTGAGCGACCTGCACGCGCACAAGCTTCGGGTGGACCCGGTCAACTTCAAG
CTCCTAAGCCACTGCCTGCTGGTGACCCTGGCCGCCCACCTCCCCGCCGAGTTCACCCCT
GCGGTGCACGCCTCCCTGGACAAGTTCCTGGCTTCTGTGAGCACCGTGCTGACCTCCAAA
TACCGTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00042</identifier>
            <name>Globin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosolic small ribosomal subunit</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>haptoglobin-hemoglobin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>hemoglobin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bicarbonate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxygen transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hydrogen peroxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers>
    <carrier position="2">
      <id>BE0000510</id>
      <name>Serotransferrin</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>carrier</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A20350</ref-id>
            <pubmed-id>17206511</pubmed-id>
            <citation>Horl WH: Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol. 2007 Apr;22(4):480-9. Epub 2007 Jan 6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02787" source="Swiss-Prot">
        <name>Serotransferrin</name>
        <general-function>Transferrin receptor binding</general-function>
        <specific-function>Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation.</specific-function>
        <gene-name>TF</gene-name>
        <locus>3q22.1</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi>7.13</theoretical-pi>
        <molecular-weight>77063.195</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11740</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TF</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M12530</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>339453</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02787</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TRFE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Beta-1 metal-binding globulin</synonym>
          <synonym>Siderophilin</synonym>
          <synonym>Transferrin</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037031|Serotransferrin
MRLAVGALLVCAVLGLCLAVPDKTVRWCAVSEHEATKCQSFRDHMKSVIPSDGPSVACVK
KASYLDCIRAIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFYGSKEDPQTFYYAVAVV
KKDSGFQMNQLRGKKSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSCAPC
ADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFVKHSTIFENLANKADRD
QYELLCLDNTRKPVDEYKDCHLAQVPSHTVVARSMGGKEDLIWELLNQAQEHFGKDKSKE
FQLFSSPHGKDLLFKDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTCPEAPTDECKP
VKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIAGK
CGLVPVLAENYNKSDNCEDTPEAGYFAIAVVKKSASDLTWDNLKGKKSCHTAVGRTAGWN
IPMGLLYNKINHCRFDEFFSEGCAPGSKKDSSLCKLCMGSGLNLCEPNNKEGYYGYTGAF
RCLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDGTRKPVEEYANCHLAR
APNHAVVTRKDKEACVHKILRQQQHLFGSNVTDCSGNFCLFRSETKDLLFRDDTVCLAKL
HDRNTYEKYLGEEYVKAVGNLRKCSTSSLLEACTFRRP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021268|Serotransferrin (TF)
ATGAGGCTCGCCGTGGGAGCCCTGCTGGTCTGCGCCGTCCTGGGGCTGTGTCTGGCTGTC
CCTGATAAAACTGTGAGATGGTGTGCAGTGTCGGAGCATGAGGCCACTAAGTGCCAGAGT
TTCCGCGACCATATGAAAAGCGTCATTCCATCCGATGGTCCCAGTGTTGCTTGTGTGAAG
AAAGCCTCCTACCTTGATTGCATCAGGGCCATTGCGGCAAACGAAGCGGATGCTGTGACA
CTGGATGCAGGTTTGGTGTATGATGCTTACCTGGCTCCCAATAACCTGAAGCCTGTGGTG
GCAGAGTTCTATGGGTCAAAAGAGGATCCACAGACTTTCTATTATGCTGTTGCTGTGGTG
AAGAAGGATAGTGGCTTCCAGATGAACCAGCTTCGAGGCAAGAAGTCCTGCCACACGGGT
CTAGGCAGGTCCGCTGGGTGGAACATCCCCATAGGCTTACTTTACTGTGACTTACCTGAG
CCACGTAAACCTCTTGAGAAAGCAGTGGCCAATTTCTTCTCGGGCAGCTGTGCCCCTTGT
GCGGATGGGACGGACTTCCCCCAGCTGTGTCAACTGTGTCCAGGGTGTGGCTGCTCCACC
CTTAACCAATACTTCGGCTACTCGGGAGCCTTCAAGTGTCTGAAGGATGGTGCTGGGGAT
GTGGCCTTTGTCAAGCACTCGACTATATTTGAGAACTTGGCAAACAAGGCTGACAGGGAC
CAGTATGAGCTGCTTTGCCTGGACAACACCCGGAAGCCGGTAGATGAATACAAGGACTGC
CACTTGGCCCAGGTCCCTTCTCATACCGTCGTGGCCCGAAGTATGGGCGGCAAGGAGGAC
TTGATCTGGGAGCTTCTCAACCAGGCCCAGGAACATTTTGGCAAAGACAAATCAAAAGAA
TTCCAACTATTCAGCTCTCCTCATGGGAAGGACCTGCTGTTTAAGGACTCTGCCCACGGG
TTTTTAAAAGTCCCCCCCAGGATGGATGCCAAGATGTACCTGGGCTATGAGTATGTCACT
GCCATCCGGAATCTACGGGAAGGCACATGCCCAGAAGCCCCAACAGATGAATGCAAGCCT
GTGAAGTGGTGTGCGCTGAGCCACCACGAGAGGCTCAAGTGTGATGAGTGGAGTGTTAAC
AGTGTAGGGAAAATAGAGTGTGTATCAGCAGAGACCACCGAAGACTGCATCGCCAAGATC
ATGAATGGAGAAGCTGATGCCATGAGCTTGGATGGAGGGTTTGTCTACATAGCGGGCAAG
TGTGGTCTGGTGCCTGTCTTGGCAGAAAACTACAATAAGAGCGATAATTGTGAGGATACA
CCAGAGGCAGGGTATTTTGCTGTAGCAGTGGTGAAGAAATCAGCTTCTGACCTCACCTGG
GACAATCTGAAAGGCAAGAAGTCCTGCCATACGGCAGTTGGCAGAACCGCTGGCTGGAAC
ATCCCCATGGGCCTGCTCTACAATAAGATCAACCACTGCAGATTTGATGAATTTTTCAGT
GAAGGTTGTGCCCCTGGGTCTAAGAAAGACTCCAGTCTCTGTAAGCTGTGTATGGGCTCA
GGCCTAAACCTGTGTGAACCCAACAACAAAGAGGGATACTACGGCTACACAGGCGCTTTC
AGGTGTCTGGTTGAGAAGGGAGATGTGGCCTTTGTGAAACACCAGACTGTCCCACAGAAC
ACTGGGGGAAAAAACCCTGATCCATGGGCTAAGAATCTGAATGAAAAAGACTATGAGTTG
CTGTGCCTTGATGGTACCAGGAAACCTGTGGAGGAGTATGCGAACTGCCACCTGGCCAGA
GCCCCGAATCACGCTGTGGTCACACGGAAAGATAAGGAAGCTTGCGTCCACAAGATATTA
CGTCAACAGCAGCACCTATTTGGAAGCAACGTAACTGACTGCTCGGGCAACTTTTGTTTG
TTCCGGTCGGAAACCAAGGACCTTCTGTTCAGAGATGACACAGTATGTTTGGCCAAACTT
CATGACAGAAACACATATGAAAAATACTTAGGAGAAGAATATGTCAAGGCTGTTGGTAAC
CTGAGAAAATGCTCCACCTCATCACTCCTGGAAGCCTGCACTTTCCGTAGACCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00405</identifier>
            <name>Transferrin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basal part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basal plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>coated pit</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic membrane-bounded vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>early endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extrinsic component of external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>HFE-transferrin receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>late endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>recycling endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ferric iron binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ferric iron transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ferrous iron binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transferrin receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to iron ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ferrous iron import into cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein stability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transferrin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters/>
</drug>